SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ACMI - Accumed Inc. -- Ignore unavailable to you. Want to Upgrade?


To: Sigmund who wrote (981)1/7/1998 3:54:00 PM
From: Frank Buck  Read Replies (1) | Respond to of 1894
 
Sigmund and Others,

I have taken Dana's suggestion to review some objective (non-Company issued) information. Here is a link that goes right to the experts in the field.

blackwell-science.com

The link is marked to an abstract of a text that has been published from an "amalgamation of published papers on HPV". The condensing of these papers (published by internationally-regarded experts) into a book format makes it a very comprehensive read. Not to mention a "one-stop-shop".

Some section titles that I thought were of interest (for-our-purposes) are reproduced below. The highlighted aspects (bold/italicized) should provide valuable insight. I am confident a local library can obtain the text (if a medical-library is not available to you).

c Blackwell Science Ltd
55 illustrations
488 pages
Hardback 0632047658
Price œ65.00
March 1997

Related Titles

New Developments in Cervical Cancer Screening and Prevention
first editionEditors:
E Franco, J Monsonego
EUROGIN (European Research Organisation on Genital Infection and Neoplasia) brings together clinicians and scientists who work on genital infections and their relationship to cancer. The aim is to promote and develop research, training, screening, prevention and information on genital infections, precancers and cancers in women.

This book reviews the latest developments in the epidemiology,
natural history and screening of cervical cancer. It also deals with management of cervical cancer, the development of vaccines against human papilloma virus - its major causative agent - and new technologies such as automated screening, HPV Testing and adjuvant tests to cytology.

The final - and most important - part of the book lists the guidelines developed by the experts for cervical cancer the reason the meeting was held.

Sixty papers presented at the EUROGIN meeting, covering the whole
scientific and clinical experience of cervical cancer


Contents

Colombia and Spain and a Challenge for the Future

Statistical Issues in Studies of Human Papillomavirus Infection and
Cervical Cancer


The Epidemiological Basis for Evaluating Screening Policies

Section 4:
Cytology Screening Programmes: Organization, Monitoring and
Use of Resources for Screening Programmes

Cervical Screening by General Practitioners and Nurses and Information
Feedback Systems

Screening Programmes: Results and Expectations

Screening for Cervical Cancer: Experience of the Nordic Countries
Screening that Failed to Work


Implementation and Evaluation of Cervical Cancer Screening Programmes in the European Union

Organization and results of Cervical Cancer Screening in Europe Over the Past 20 Years

Spontaneous Screening: Benefits and Limitations

Is Cervical Cancer Cytological Screening Valuable in Developing
Countries?


Screening in Cervical Cancer Prevention in Porto Alegre, Brazil: The Experience of a Programme in a Developing Country

Section 5:

Automation in Cytology: Automation and Cervical Cytopathology: An Overview

Automation in Cervicovaginal Cytology: System Requirements and Benefits

Automated Screening using the AutoPap 300 Device

Liquid-based Cytology: Comparison of ThinPrep 2000 with Conventionally Prepared Pap Smears

The History of Neural Network Technology in Cytology

A Comparison of Automated and Manual Screening: Theoretical
Considerations


Cooperation of the Image Analyser and the Cytologist

Advantages and Limitations of Automated Screening Systems in Developing and Developed Countries

Section 6:
Human Papillomavirus Testing: Methods of DNA Hybridization
and their Clinical Applicability to Human Papillomavirus Detection

Human Papillomavirus Testing for Primary Cervical Cancer Screening

Human Papillomavirus DNA Testing Using Liquid-based Cytology

Human Papillomavirus Testing for Diagnostic Triage of Minor-grade
Cytological Abnormalities: The European Perspective

Use of Human Papillomavirus Tying for Quality Assurance of Cytological Diagnosis Estimates of the Cost Impact of Introducing Human Papillomavirus Testing into a Cervical Screening Programme Viral Load as a Surrogate for Persistence in Cervical Human Papillomavirus

Infection Molecular Variant Analysis as a Tool in Natural History Studies of Human Papillomavirus Infection and Cervical Neoplasia

Happy reading,

Frank